25 XP   0   0   10

Staidson Beijing Biopharma
Buy, Hold or Sell?

Let's analyse Staidson together

PenkeI guess you are interested in Staidson Beijing Biopharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Staidson Beijing Biopharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Staidson Beijing Biopharma

I send you an email if I find something interesting about Staidson Beijing Biopharma.

Quick analysis of Staidson (30 sec.)










What can you expect buying and holding a share of Staidson? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
85.0%

What is your share worth?

Current worth
¥2.47
Expected worth in 1 year
¥2.03
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
¥-0.43
Return On Investment
-6.4%

For what price can you sell your share?

Current Price per Share
¥6.76
Expected price per share
¥5.47 - ¥7.89
How sure are you?
50%

1. Valuation of Staidson (5 min.)




Live pricePrice per Share (EOD)

¥6.76

Intrinsic Value Per Share

¥-4.77 - ¥2.32

Total Value Per Share

¥-2.30 - ¥4.79

2. Growth of Staidson (5 min.)




Is Staidson growing?

Current yearPrevious yearGrowGrow %
How rich?$163m$201.6m-$27.5m-15.8%

How much money is Staidson making?

Current yearPrevious yearGrowGrow %
Making money-$7.8m-$5.7m-$2m-26.7%
Net Profit Margin-57.7%-31.8%--

How much money comes from the company's main activities?

3. Financial Health of Staidson (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#294 / 1031

Most Revenue
#243 / 1031

Most Profit
#545 / 1031

Most Efficient
#566 / 1031

What can you expect buying and holding a share of Staidson? (5 min.)

Welcome investor! Staidson's management wants to use your money to grow the business. In return you get a share of Staidson.

What can you expect buying and holding a share of Staidson?

First you should know what it really means to hold a share of Staidson. And how you can make/lose money.

Speculation

The Price per Share of Staidson is ¥6.76. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Staidson.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Staidson, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥2.47. Based on the TTM, the Book Value Change Per Share is ¥-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Staidson.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.01-0.1%-0.02-0.3%-0.01-0.2%-0.01-0.1%0.000.0%
Usd Book Value Change Per Share-0.01-0.2%-0.01-0.2%0.00-0.1%-0.02-0.3%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.1%0.010.1%
Usd Total Gains Per Share-0.01-0.2%-0.01-0.2%0.00-0.1%-0.01-0.2%0.010.1%
Usd Price Per Share1.40-1.52-2.19-1.69-2.28-
Price to Earnings Ratio-38.25--24.99--83.28--9.71-18.90-
Price-to-Total Gains Ratio-108.66--117.81--84.34--389.93--126.60-
Price to Book Ratio4.10-4.17-5.15-3.80-4.88-
Price-to-Total Gains Ratio-108.66--117.81--84.34--389.93--126.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.935584
Number of shares1068
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.01-0.02
Usd Total Gains Per Share-0.01-0.01
Gains per Quarter (1068 shares)-15.97-14.39
Gains per Year (1068 shares)-63.88-57.57
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-64-7420-77-68
20-128-13839-154-126
30-192-20259-231-184
40-256-26678-309-242
50-320-33098-386-300
60-384-394117-463-358
71-448-458137-540-416
81-512-522157-617-474
91-576-586176-694-532
101-640-650196-771-590

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%23.016.01.057.5%34.016.01.066.7%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%21.019.00.052.5%31.020.00.060.8%
Dividend per Share4.00.00.0100.0%10.00.02.083.3%17.00.03.085.0%34.00.06.085.0%42.00.09.082.4%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%24.016.00.060.0%35.016.00.068.6%

Fundamentals of Staidson

About Staidson Beijing Biopharma

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

Fundamental data was last updated by Penke on 2024-03-25 22:53:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Staidson Beijing Biopharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Staidson earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Staidson to the Biotechnology industry mean.
  • A Net Profit Margin of -30.0% means that ¥-0.30 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Staidson Beijing Biopharma:

  • The MRQ is -30.0%. The company is making a huge loss. -2
  • The TTM is -57.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-30.0%TTM-57.7%+27.7%
TTM-57.7%YOY-31.8%-25.8%
TTM-57.7%5Y-27.8%-29.9%
5Y-27.8%10Y-5.3%-22.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.0%-159.2%+129.2%
TTM-57.7%-202.3%+144.6%
YOY-31.8%-263.0%+231.2%
5Y-27.8%-452.4%+424.6%
10Y-5.3%-589.0%+583.7%
1.1.2. Return on Assets

Shows how efficient Staidson is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Staidson to the Biotechnology industry mean.
  • -2.1% Return on Assets means that Staidson generated ¥-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Staidson Beijing Biopharma:

  • The MRQ is -2.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM-3.7%+1.5%
TTM-3.7%YOY-2.5%-1.2%
TTM-3.7%5Y-1.9%-1.8%
5Y-1.9%10Y0.3%-2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%-12.5%+10.4%
TTM-3.7%-12.2%+8.5%
YOY-2.5%-11.2%+8.7%
5Y-1.9%-13.3%+11.4%
10Y0.3%-14.6%+14.9%
1.1.3. Return on Equity

Shows how efficient Staidson is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Staidson to the Biotechnology industry mean.
  • -2.7% Return on Equity means Staidson generated ¥-0.03 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Staidson Beijing Biopharma:

  • The MRQ is -2.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.7%TTM-4.5%+1.9%
TTM-4.5%YOY-2.9%-1.6%
TTM-4.5%5Y-2.3%-2.3%
5Y-2.3%10Y0.4%-2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.7%-16.0%+13.3%
TTM-4.5%-15.8%+11.3%
YOY-2.9%-13.9%+11.0%
5Y-2.3%-18.2%+15.9%
10Y0.4%-19.1%+19.5%

1.2. Operating Efficiency of Staidson Beijing Biopharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Staidson is operating .

  • Measures how much profit Staidson makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Staidson to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Staidson Beijing Biopharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-35.9%+35.9%
TTM-35.9%YOY-47.4%+11.4%
TTM-35.9%5Y-29.4%-6.5%
5Y-29.4%10Y-14.1%-15.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM-35.9%-208.5%+172.6%
YOY-47.4%-280.2%+232.8%
5Y-29.4%-459.9%+430.5%
10Y-14.1%-596.9%+582.8%
1.2.2. Operating Ratio

Measures how efficient Staidson is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.50 means that the operating costs are ¥1.50 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Staidson Beijing Biopharma:

  • The MRQ is 1.501. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.789. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.501TTM1.789-0.287
TTM1.789YOY1.641+0.147
TTM1.7895Y1.515+0.274
5Y1.51510Y0.830+0.685
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5012.817-1.316
TTM1.7893.181-1.392
YOY1.6413.609-1.968
5Y1.5155.554-4.039
10Y0.8307.396-6.566

1.3. Liquidity of Staidson Beijing Biopharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Staidson is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.92 means the company has ¥1.92 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Staidson Beijing Biopharma:

  • The MRQ is 1.917. The company is able to pay all its short-term debts. +1
  • The TTM is 2.144. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.917TTM2.144-0.226
TTM2.144YOY3.510-1.366
TTM2.1445Y4.422-2.278
5Y4.42210Y2.496+1.926
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9173.987-2.070
TTM2.1444.440-2.296
YOY3.5105.569-2.059
5Y4.4226.158-1.736
10Y2.4966.492-3.996
1.3.2. Quick Ratio

Measures if Staidson is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Staidson to the Biotechnology industry mean.
  • A Quick Ratio of 0.31 means the company can pay off ¥0.31 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Staidson Beijing Biopharma:

  • The MRQ is 0.307. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.576. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.307TTM0.576-0.269
TTM0.576YOY2.230-1.654
TTM0.5765Y2.112-1.536
5Y2.11210Y1.661+0.451
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3073.653-3.346
TTM0.5764.158-3.582
YOY2.2305.515-3.285
5Y2.1126.012-3.900
10Y1.6616.206-4.545

1.4. Solvency of Staidson Beijing Biopharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Staidson assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Staidson to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.21 means that Staidson assets are financed with 20.8% credit (debt) and the remaining percentage (100% - 20.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Staidson Beijing Biopharma:

  • The MRQ is 0.208. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.192. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.208TTM0.192+0.016
TTM0.192YOY0.152+0.040
TTM0.1925Y0.145+0.047
5Y0.14510Y0.156-0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2080.336-0.128
TTM0.1920.330-0.138
YOY0.1520.267-0.115
5Y0.1450.367-0.222
10Y0.1560.378-0.222
1.4.2. Debt to Equity Ratio

Measures if Staidson is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Staidson to the Biotechnology industry mean.
  • A Debt to Equity ratio of 26.2% means that company has ¥0.26 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Staidson Beijing Biopharma:

  • The MRQ is 0.262. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.238. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.262TTM0.238+0.024
TTM0.238YOY0.179+0.059
TTM0.2385Y0.171+0.067
5Y0.17110Y0.187-0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2620.376-0.114
TTM0.2380.398-0.160
YOY0.1790.334-0.155
5Y0.1710.431-0.260
10Y0.1870.476-0.289

2. Market Valuation of Staidson Beijing Biopharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Staidson generates.

  • Above 15 is considered overpriced but always compare Staidson to the Biotechnology industry mean.
  • A PE ratio of -38.25 means the investor is paying ¥-38.25 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Staidson Beijing Biopharma:

  • The EOD is -25.601. Based on the earnings, the company is expensive. -2
  • The MRQ is -38.250. Based on the earnings, the company is expensive. -2
  • The TTM is -24.993. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-25.601MRQ-38.250+12.649
MRQ-38.250TTM-24.993-13.257
TTM-24.993YOY-83.275+58.282
TTM-24.9935Y-9.711-15.282
5Y-9.71110Y18.900-28.611
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-25.601-2.697-22.904
MRQ-38.250-2.422-35.828
TTM-24.993-2.709-22.284
YOY-83.275-4.116-79.159
5Y-9.711-6.257-3.454
10Y18.900-6.478+25.378
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Staidson Beijing Biopharma:

  • The EOD is -21.890. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -32.705. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -24.969. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-21.890MRQ-32.705+10.815
MRQ-32.705TTM-24.969-7.736
TTM-24.969YOY-33.717+8.749
TTM-24.9695Y-265.321+240.352
5Y-265.32110Y-132.425-132.896
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-21.890-3.344-18.546
MRQ-32.705-2.939-29.766
TTM-24.969-3.486-21.483
YOY-33.717-5.592-28.125
5Y-265.321-8.464-256.857
10Y-132.425-8.872-123.553
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Staidson is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.10 means the investor is paying ¥4.10 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Staidson Beijing Biopharma:

  • The EOD is 2.741. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.095. Based on the equity, the company is fair priced.
  • The TTM is 4.166. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.741MRQ4.095-1.354
MRQ4.095TTM4.166-0.070
TTM4.166YOY5.154-0.988
TTM4.1665Y3.802+0.364
5Y3.80210Y4.877-1.075
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7412.198+0.543
MRQ4.0952.042+2.053
TTM4.1662.121+2.045
YOY5.1542.907+2.247
5Y3.8023.682+0.120
10Y4.8774.114+0.763
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Staidson Beijing Biopharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.093-0.108+16%-0.031-66%-0.130+40%-0.006-93%
Book Value Per Share--2.4662.632-6%3.049-19%3.294-25%3.517-30%
Current Ratio--1.9172.144-11%3.510-45%4.422-57%2.496-23%
Debt To Asset Ratio--0.2080.192+8%0.152+37%0.145+43%0.156+33%
Debt To Equity Ratio--0.2620.238+10%0.179+46%0.171+53%0.187+40%
Dividend Per Share--0.0000.000+243%0.000+5652%0.033-99%0.065-99%
Eps---0.066-0.148+124%-0.087+32%-0.070+6%0.020-432%
Free Cash Flow Per Share---0.077-0.116+50%-0.122+58%-0.098+27%0.072-208%
Free Cash Flow To Equity Per Share---0.077-0.066-15%-0.114+48%-0.118+53%0.061-227%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max--2.321--------
Intrinsic Value_10Y_min---4.766--------
Intrinsic Value_1Y_max--0.280--------
Intrinsic Value_1Y_min---0.465--------
Intrinsic Value_3Y_max--0.804--------
Intrinsic Value_3Y_min---1.416--------
Intrinsic Value_5Y_max--1.286--------
Intrinsic Value_5Y_min---2.381--------
Market Cap3229745425.920-49%4825507219.2005256697344.480-8%7559563165.920-36%5822141680.512-17%7866482147.116-39%
Net Profit Margin---0.300-0.577+92%-0.318+6%-0.278-7%-0.053-82%
Operating Margin----0.3590%-0.4740%-0.2940%-0.1410%
Operating Ratio--1.5011.789-16%1.641-9%1.515-1%0.830+81%
Pb Ratio2.741-49%4.0954.166-2%5.154-21%3.802+8%4.877-16%
Pe Ratio-25.601+33%-38.250-24.993-35%-83.275+118%-9.711-75%18.900-302%
Price Per Share6.760-49%10.10011.003-8%15.823-36%12.186-17%16.465-39%
Price To Free Cash Flow Ratio-21.890+33%-32.705-24.969-24%-33.717+3%-265.321+711%-132.425+305%
Price To Total Gains Ratio-72.727+33%-108.660-117.813+8%-84.337-22%-389.930+259%-126.597+17%
Quick Ratio--0.3070.576-47%2.230-86%2.112-85%1.661-82%
Return On Assets---0.021-0.037+73%-0.025+17%-0.019-11%0.003-837%
Return On Equity---0.027-0.045+70%-0.029+10%-0.023-16%0.004-838%
Total Gains Per Share---0.093-0.108+16%-0.031-66%-0.097+5%0.058-260%
Usd Book Value--163070205.071174049208.971-6%201610794.986-19%217835287.456-25%232538005.418-30%
Usd Book Value Change Per Share---0.013-0.015+16%-0.004-66%-0.018+40%-0.001-93%
Usd Book Value Per Share--0.3410.364-6%0.422-19%0.456-25%0.487-30%
Usd Dividend Per Share--0.0000.000+243%0.000+5652%0.005-99%0.009-99%
Usd Eps---0.009-0.021+124%-0.012+32%-0.010+6%0.003-432%
Usd Free Cash Flow---5105088.098-7680235.103+50%-8084191.475+58%-6491636.347+27%4748078.970-208%
Usd Free Cash Flow Per Share---0.011-0.016+50%-0.017+58%-0.014+27%0.010-208%
Usd Free Cash Flow To Equity Per Share---0.011-0.009-15%-0.016+48%-0.016+53%0.008-227%
Usd Market Cap446996766.947-49%667850199.137727526912.476-8%1046243542.163-36%805784408.583-17%1088721129.161-39%
Usd Price Per Share0.936-49%1.3981.523-8%2.190-36%1.687-17%2.279-39%
Usd Profit---4364993.770-7857864.844+80%-5759633.302+32%-4220453.935-3%1507233.210-390%
Usd Revenue--14544051.09015242051.728-5%18715074.753-22%18451409.312-21%30072554.327-52%
Usd Total Gains Per Share---0.013-0.015+16%-0.004-66%-0.013+5%0.008-260%
 EOD+3 -5MRQTTM+21 -13YOY+16 -185Y+15 -1910Y+5 -30

3.2. Fundamental Score

Let's check the fundamental score of Staidson Beijing Biopharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-25.601
Price to Book Ratio (EOD)Between0-12.741
Net Profit Margin (MRQ)Greater than0-0.300
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.307
Current Ratio (MRQ)Greater than11.917
Debt to Asset Ratio (MRQ)Less than10.208
Debt to Equity Ratio (MRQ)Less than10.262
Return on Equity (MRQ)Greater than0.15-0.027
Return on Assets (MRQ)Greater than0.05-0.021
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Staidson Beijing Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.800
Ma 20Greater thanMa 507.205
Ma 50Greater thanMa 1007.515
Ma 100Greater thanMa 2009.110
OpenGreater thanClose6.740
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Retained Earnings  356,862-42,247314,615-217,89096,72565,043161,769-200,694-38,925
Net Interest Income  53721558124682-82600-626-26



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets1,487,276
Total Liabilities309,023
Total Stockholder Equity1,178,253
 As reported
Total Liabilities 309,023
Total Stockholder Equity+ 1,178,253
Total Assets = 1,487,276

Assets

Total Assets1,487,276
Total Current Assets439,660
Long-term Assets1,047,616
Total Current Assets
Cash And Cash Equivalents 196,557
Net Receivables 70,301
Inventory 28,986
Other Current Assets 1,793
Total Current Assets  (as reported)439,660
Total Current Assets  (calculated)297,638
+/- 142,022
Long-term Assets
Property Plant Equipment 270,879
Goodwill 19,753
Intangible Assets 82,893
Long-term Assets Other 1,499
Long-term Assets  (as reported)1,047,616
Long-term Assets  (calculated)375,023
+/- 672,593

Liabilities & Shareholders' Equity

Total Current Liabilities229,306
Long-term Liabilities79,717
Total Stockholder Equity1,178,253
Total Current Liabilities
Short Long Term Debt 53,797
Accounts payable 68,827
Other Current Liabilities 56,601
Total Current Liabilities  (as reported)229,306
Total Current Liabilities  (calculated)179,225
+/- 50,081
Long-term Liabilities
Long-term Liabilities  (as reported)79,717
Long-term Liabilities  (calculated)0
+/- 79,717
Total Stockholder Equity
Total Stockholder Equity (as reported)1,178,253
Total Stockholder Equity (calculated)0
+/- 1,178,253
Other
Capital Stock477,773
Common Stock Shares Outstanding 477,773
Net Invested Capital 1,232,050
Net Working Capital 210,353
Property Plant and Equipment Gross 270,879



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312009-12-312008-12-31
> Total Assets 
92,067
148,751
264,884
292,262
1,070,191
1,093,959
1,149,400
1,190,628
1,218,639
1,268,843
1,432,962
1,454,433
1,475,766
1,503,544
1,569,472
1,604,687
1,659,672
1,726,878
1,811,919
1,826,763
1,819,842
1,940,125
2,070,856
2,131,325
2,104,216
2,238,773
2,350,596
2,434,078
2,414,867
2,476,535
2,628,520
2,602,495
2,748,999
2,771,287
2,772,144
2,759,209
1,864,882
1,849,724
1,862,414
1,794,619
1,839,675
1,816,488
1,856,206
1,798,104
1,716,471
1,674,624
1,826,985
1,737,203
1,662,011
1,643,970
1,669,315
1,540,577
1,526,868
1,487,276
1,487,2761,526,8681,540,5771,669,3151,643,9701,662,0111,737,2031,826,9851,674,6241,716,4711,798,1041,856,2061,816,4881,839,6751,794,6191,862,4141,849,7241,864,8822,759,2092,772,1442,771,2872,748,9992,602,4952,628,5202,476,5352,414,8672,434,0782,350,5962,238,7732,104,2162,131,3252,070,8561,940,1251,819,8421,826,7631,811,9191,726,8781,659,6721,604,6871,569,4721,503,5441,475,7661,454,4331,432,9621,268,8431,218,6391,190,6281,149,4001,093,9591,070,191292,262264,884148,75192,067
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,655,684
1,587,318
1,552,806
1,457,863
1,162,911
1,074,631
1,021,175
936,473
953,707
980,700
903,322
850,928
778,214
741,118
688,444
647,371
574,364
538,557
529,058
447,292
431,452
439,660
439,660431,452447,292529,058538,557574,364647,371688,444741,118778,214850,928903,322980,700953,707936,4731,021,1751,074,6311,162,9111,457,8631,552,8061,587,3181,655,68400000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
229,442
568,403
365,201
266,646
252,389
137,925
352,614
117,189
69,259
191,142
140,574
176,426
119,885
120,533
85,011
103,317
161,407
185,134
264,988
212,005
183,804
196,557
196,557183,804212,005264,988185,134161,407103,31785,011120,533119,885176,426140,574191,14269,259117,189352,614137,925252,389266,646365,201568,403229,44200000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
551,109
0
480,846
0
483,703
0
275,002
425,029
486,595
551,445
461,244
370,461
341,976
321,903
381,456
301,523
200,384
130,397
0
0
0
0
0000130,397200,384301,523381,456321,903341,976370,461461,244551,445486,595425,029275,0020483,7030480,8460551,10900000000000000000000000000000000
       Net Receivables 
15,275
21,496
11,414
11,981
20,032
29,259
52,465
69,319
89,058
99,015
215,345
219,892
248,405
293,279
275,623
273,598
319,400
336,188
341,623
308,007
283,098
327,890
375,970
323,391
370,429
402,833
435,914
398,358
445,977
439,397
378,176
337,504
261,555
232,420
211,694
107,361
117,582
115,191
168,752
76,042
114,207
130,979
129,515
112,167
146,664
147,274
159,074
124,235
129,469
145,236
189,557
105,245
135,143
70,301
70,301135,143105,245189,557145,236129,469124,235159,074147,274146,664112,167129,515130,979114,20776,042168,752115,191117,582107,361211,694232,420261,555337,504378,176439,397445,977398,358435,914402,833370,429323,391375,970327,890283,098308,007341,623336,188319,400273,598275,623293,279248,405219,892215,34599,01589,05869,31952,46529,25920,03211,98111,41421,49615,275
       Other Current Assets 
1,454
1,355
897
5,283
2,616
1,765
1,545
914
1,567
1,415
72,284
72,536
171,692
156,383
102,312
155,032
202,484
205,213
204,586
260,061
260,541
208,831
286,083
365,727
408,696
962,432
415,565
1,022,394
368,252
756,989
726,671
950,248
577,845
749,457
451,726
982,011
679,331
709,523
11,492
265,289
26,307
59,293
13,168
150,559
20,861
125,909
37,896
88,512
54,777
50,282
55,685
1,819
79,421
1,793
1,79379,4211,81955,68550,28254,77788,51237,896125,90920,861150,55913,16859,29326,307265,28911,492709,523679,331982,011451,726749,457577,845950,248726,671756,989368,2521,022,394415,565962,432408,696365,727286,083208,831260,541260,061204,586205,213202,484155,032102,312156,383171,69272,53672,2841,4151,5679141,5451,7652,6165,2838971,3551,454
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,301,345
701,971
775,092
841,239
858,147
885,968
835,788
952,883
947,176
938,257
933,506
1,138,541
1,089,831
1,087,647
1,105,413
1,140,257
1,093,284
1,095,415
1,047,616
1,047,6161,095,4151,093,2841,140,2571,105,4131,087,6471,089,8311,138,541933,506938,257947,176952,883835,788885,968858,147841,239775,092701,9711,301,34500000000000000000000000000000000000
       Property Plant Equipment 
23,351
34,244
133,615
136,284
168,693
171,004
210,083
210,009
244,909
237,957
243,446
238,376
255,349
244,010
258,461
245,631
242,532
241,088
238,782
238,981
240,228
239,349
240,244
239,987
242,953
244,142
243,412
245,019
243,135
244,448
247,298
253,127
263,938
276,621
298,683
298,944
303,176
311,559
317,176
314,483
308,930
302,229
295,170
301,924
307,878
308,360
312,429
312,046
310,636
317,712
290,583
283,112
273,519
270,879
270,879273,519283,112290,583317,712310,636312,046312,429308,360307,878301,924295,170302,229308,930314,483317,176311,559303,176298,944298,683276,621263,938253,127247,298244,448243,135245,019243,412244,142242,953239,987240,244239,349240,228238,981238,782241,088242,532245,631258,461244,010255,349238,376243,446237,957244,909210,009210,083171,004168,693136,284133,61534,24423,351
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,348
9,348
9,348
0
0
0
4,169
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
19,753
22,174
22,174
22,174
22,174
22,174
22,174
22,174
22,174
22,174
22,174
22,174
22,174
19,753
19,753
19,753
19,753
19,75319,75319,75319,75322,17422,17422,17422,17422,17422,17422,17422,17422,17422,17422,17422,17419,75319,75319,75319,75319,75319,75319,75319,75319,75319,75319,75319,75319,75319,75319,75319,7534,1690009,3489,3489,348000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
699,469
760,246
792,604
808,230
269,715
334,463
380,771
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000380,771334,463269,715808,230792,604760,246699,46900000000000000000000000000000000
       Intangible Assets 
31,328
28,344
9,132
26,184
7,566
24,430
5,989
22,639
4,425
66,506
49,070
72,231
48,167
71,435
48,359
71,849
71,739
71,629
62,171
62,061
62,145
100,848
57,145
57,030
56,916
56,801
56,686
56,571
56,457
59,842
56,227
56,113
36,246
36,300
36,161
45,865
34,967
49,597
50,336
52,559
101,581
102,211
103,096
104,484
105,147
105,130
87,337
88,707
94,789
103,349
107,223
111,269
74,378
82,893
82,89374,378111,269107,223103,34994,78988,70787,337105,130105,147104,484103,096102,211101,58152,55950,33649,59734,96745,86536,16136,30036,24656,11356,22759,84256,45756,57156,68656,80156,91657,03057,145100,84862,14562,06162,17171,62971,73971,84948,35971,43548,16772,23149,07066,5064,42522,6395,98924,4307,56626,1849,13228,34431,328
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
98,777
32,222
30,093
27,609
49,200
2,475
311,300
8,166
20,851
15,268
19,016
15,154
15,439
15,821
2,057
2,093
2,124
1,352
1,499
1,4991,3522,1242,0932,05715,82115,43915,15419,01615,26820,8518,166311,3002,47549,20027,60930,09332,22298,77700000000000000000000000000000000000
> Total Liabilities 
29,249
29,034
98,656
114,457
39,837
37,949
47,322
49,952
57,730
73,239
192,148
165,695
191,839
201,297
255,473
254,947
280,063
284,110
297,541
261,850
268,215
289,281
387,059
393,966
365,722
414,568
432,322
444,911
442,010
497,042
419,142
471,263
397,671
346,319
314,301
311,597
234,280
220,014
227,182
187,208
249,181
260,140
268,700
255,947
224,581
229,567
276,246
259,521
248,506
258,993
315,452
265,243
303,993
309,023
309,023303,993265,243315,452258,993248,506259,521276,246229,567224,581255,947268,700260,140249,181187,208227,182220,014234,280311,597314,301346,319397,671471,263419,142497,042442,010444,911432,322414,568365,722393,966387,059289,281268,215261,850297,541284,110280,063254,947255,473201,297191,839165,695192,14873,23957,73049,95247,32237,94939,837114,45798,65629,03429,249
   > Total Current Liabilities 
24,749
24,534
26,656
16,257
19,137
17,249
26,622
29,252
37,030
52,539
157,480
131,027
157,171
165,107
218,950
218,558
240,400
244,114
257,680
222,124
228,024
240,467
353,365
360,445
332,373
381,657
399,084
408,845
406,117
461,321
348,129
401,410
312,753
259,827
232,664
222,767
183,151
174,403
178,372
138,496
198,068
213,250
208,197
188,654
158,272
167,513
196,639
170,838
159,331
171,310
231,774
182,633
224,054
229,306
229,306224,054182,633231,774171,310159,331170,838196,639167,513158,272188,654208,197213,250198,068138,496178,372174,403183,151222,767232,664259,827312,753401,410348,129461,321406,117408,845399,084381,657332,373360,445353,365240,467228,024222,124257,680244,114240,400218,558218,950165,107157,171131,027157,48052,53937,03029,25226,62217,24919,13716,25726,65624,53424,749
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,607
3,640
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000003,6403,6070000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,607
3,640
0
48,000
51,405
48,000
48,000
0
0
0
0
0
5,680
0
0
39,669
53,797
53,79739,669005,6800000048,00048,00051,40548,00003,6403,6070000000000000000000000000000000000000
       Accounts payable 
2,130
1,112
1,956
2,255
2,394
1,631
669
2,309
1,689
1,413
1,969
2,196
3,421
3,960
3,881
2,131
2,718
4,907
7,056
2,866
3,211
4,489
4,111
5,532
8,934
8,059
6,349
7,217
6,545
5,004
4,696
3,902
4,967
9,634
18,186
13,733
13,324
18,087
12,476
9,965
13,186
14,045
19,634
12,424
23,516
24,117
31,710
26,803
28,656
33,787
35,868
35,116
69,406
68,827
68,82769,40635,11635,86833,78728,65626,80331,71024,11723,51612,42419,63414,04513,1869,96512,47618,08713,32413,73318,1869,6344,9673,9024,6965,0046,5457,2176,3498,0598,9345,5324,1114,4893,2112,8667,0564,9072,7182,1313,8813,9603,4212,1961,9691,4131,6892,3096691,6312,3942,2551,9561,1122,130
       Other Current Liabilities 
22,619
12,422
14,700
14,002
16,743
15,618
25,953
26,943
35,341
51,126
155,511
128,831
153,750
161,147
215,069
216,428
237,682
239,207
250,623
219,258
224,813
235,977
349,254
354,913
323,439
366,921
392,736
401,629
399,572
456,317
343,433
397,507
46,810
43,258
22,285
171,465
142,464
137,433
15,544
14,942
12,917
17,402
12,576
113,611
17,681
129,892
12,666
125,944
110,598
114,704
34,487
88,895
17,148
56,601
56,60117,14888,89534,487114,704110,598125,94412,666129,89217,681113,61112,57617,40212,91714,94215,544137,433142,464171,46522,28543,25846,810397,507343,433456,317399,572401,629392,736366,921323,439354,913349,254235,977224,813219,258250,623239,207237,682216,428215,069161,147153,750128,831155,51151,12635,34126,94325,95315,61816,74314,00214,70012,42222,619
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
88,831
51,128
45,611
48,811
48,712
51,112
46,890
60,502
67,292
66,308
62,054
79,607
88,683
89,176
87,683
83,679
82,610
79,939
79,717
79,71779,93982,61083,67987,68389,17688,68379,60762,05466,30867,29260,50246,89051,11248,71248,81145,61151,12888,83100000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-3,607
-3,640
0
0
0
0
7,181
6,600
6,048
5,372
4,752
4,376
3,938
3,179
2,432
0
0
002,4323,1793,9384,3764,7525,3726,0486,6007,1810000-3,640-3,6070000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,351
0
0
0
0
0
0
0
0
0
0
00000000003,3510000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
325
7,573
9,820
10,062
11,272
12,864
14,024
15,900
18,213
19,135
20,506
21,238
22,337
22,711
5,289
7,096
13,537
22,414
26,966
0
38,929
0
038,929026,96622,41413,5377,0965,28922,71122,33721,23820,50619,13518,21315,90014,02412,86411,27210,0629,8207,57332500000000000000000000000000000000
> Total Stockholder Equity
62,818
119,716
166,228
177,805
1,030,354
1,056,010
1,102,079
1,140,676
1,160,909
1,195,604
1,240,814
1,288,737
1,283,927
1,302,248
1,313,999
1,349,740
1,379,609
1,442,768
1,514,378
1,564,914
1,551,627
1,620,290
1,665,293
1,719,167
1,721,015
1,807,195
1,902,173
1,973,834
1,959,119
1,979,493
2,209,377
2,131,232
2,351,329
2,424,968
2,457,843
2,447,611
1,630,603
1,629,710
1,635,231
1,607,411
1,590,494
1,556,347
1,587,506
1,542,157
1,491,890
1,445,057
1,550,739
1,477,681
1,413,504
1,384,977
1,353,863
1,275,334
1,222,875
1,178,253
1,178,2531,222,8751,275,3341,353,8631,384,9771,413,5041,477,6811,550,7391,445,0571,491,8901,542,1571,587,5061,556,3471,590,4941,607,4111,635,2311,629,7101,630,6032,447,6112,457,8432,424,9682,351,3292,131,2322,209,3771,979,4931,959,1191,973,8341,902,1731,807,1951,721,0151,719,1671,665,2931,620,2901,551,6271,564,9141,514,3781,442,7681,379,6091,349,7401,313,9991,302,2481,283,9271,288,7371,240,8141,195,6041,160,9091,140,6761,102,0791,056,0101,030,354177,805166,228119,71662,818
   Common Stock
37,500
50,000
50,000
50,000
66,700
66,700
66,700
66,700
133,400
133,400
133,400
133,400
240,120
240,120
240,120
240,120
240,120
240,120
240,120
240,120
336,168
336,168
339,718
340,128
475,950
475,950
478,573
478,573
478,158
478,158
477,812
477,812
476,829
476,829
476,705
476,705
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
476,035
475,358
0
475,358
0
0475,3580475,358476,035476,035476,035476,035476,035476,035476,035476,035476,035476,035476,035476,035476,035476,035476,705476,705476,829476,829477,812477,812478,158478,158478,573478,573475,950475,950340,128339,718336,168336,168240,120240,120240,120240,120240,120240,120240,120240,120133,400133,400133,400133,40066,70066,70066,70066,70050,00050,00050,00037,500
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000-14,411-14,411-26,540-26,962-49,864-49,864-55,167-60,018-59,803-59,803-61,620-56,7290000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
338,874
390,452
418,465
425,571
-65,913
-72,212
-52,866
-55,948
-22,844
-41,894
15,110
-10,515
-20,813
-39,671
70,968
21,927
16,088
32,752
44,530
0
66,389
0
066,389044,53032,75216,08821,92770,968-39,671-20,813-10,51515,110-41,894-22,844-55,948-52,866-72,212-65,913425,571418,465390,452338,87400000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue440,522
Cost of Revenue-79,100
Gross Profit361,422361,422
 
Operating Income (+$)
Gross Profit361,422
Operating Expense-690,624
Operating Income-250,102-329,202
 
Operating Expense (+$)
Research Development354,786
Selling General Administrative223,546
Selling And Marketing Expenses-
Operating Expense690,624578,332
 
Net Interest Income (+$)
Interest Income790
Interest Expense-852
Other Finance Cost-1,875
Net Interest Income1,814
 
Pretax Income (+$)
Operating Income-250,102
Net Interest Income1,814
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-271,479-250,102
EBIT - interestExpense = -852
-227,106
-226,254
Interest Expense852
Earnings Before Interest and Taxes (EBIT)--270,628
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-271,479
Tax Provision--44,374
Net Income From Continuing Ops-227,106-227,106
Net Income-227,106
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--1,814
 

Technical Analysis of Staidson
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Staidson. The general trend of Staidson is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Staidson's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Staidson Beijing Biopharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 6.78 < 7.85 < 7.89.

The bearish price targets are: 5.47.

Tweet this
Staidson Beijing Biopharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Staidson Beijing Biopharma. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Staidson Beijing Biopharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Staidson Beijing Biopharma. The current macd is -0.16924595.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Staidson price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Staidson. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Staidson price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Staidson Beijing Biopharma Daily Moving Average Convergence/Divergence (MACD) ChartStaidson Beijing Biopharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Staidson Beijing Biopharma. The current adx is 22.34.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Staidson shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Staidson Beijing Biopharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Staidson Beijing Biopharma. The current sar is 7.73905536.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Staidson Beijing Biopharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Staidson Beijing Biopharma. The current rsi is 38.80. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Staidson Beijing Biopharma Daily Relative Strength Index (RSI) ChartStaidson Beijing Biopharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Staidson Beijing Biopharma. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Staidson price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Staidson Beijing Biopharma Daily Stochastic Oscillator ChartStaidson Beijing Biopharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Staidson Beijing Biopharma. The current cci is -105.9179429.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Staidson Beijing Biopharma Daily Commodity Channel Index (CCI) ChartStaidson Beijing Biopharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Staidson Beijing Biopharma. The current cmo is -30.36502719.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Staidson Beijing Biopharma Daily Chande Momentum Oscillator (CMO) ChartStaidson Beijing Biopharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Staidson Beijing Biopharma. The current willr is -81.29496403.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Staidson Beijing Biopharma Daily Williams %R ChartStaidson Beijing Biopharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Staidson Beijing Biopharma.

Staidson Beijing Biopharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Staidson Beijing Biopharma. The current atr is 0.36978134.

Staidson Beijing Biopharma Daily Average True Range (ATR) ChartStaidson Beijing Biopharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Staidson Beijing Biopharma. The current obv is -332,113,965.

Staidson Beijing Biopharma Daily On-Balance Volume (OBV) ChartStaidson Beijing Biopharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Staidson Beijing Biopharma. The current mfi is 49.95.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Staidson Beijing Biopharma Daily Money Flow Index (MFI) ChartStaidson Beijing Biopharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Staidson Beijing Biopharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Staidson Beijing Biopharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Staidson Beijing Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.800
Ma 20Greater thanMa 507.205
Ma 50Greater thanMa 1007.515
Ma 100Greater thanMa 2009.110
OpenGreater thanClose6.740
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Staidson with someone you think should read this too:
  • Are you bullish or bearish on Staidson? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Staidson? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Staidson Beijing Biopharma

I send you an email if I find something interesting about Staidson Beijing Biopharma.


Comments

How you think about this?

Leave a comment

Stay informed about Staidson Beijing Biopharma.

Receive notifications about Staidson Beijing Biopharma in your mailbox!